The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia

Atherosclerosis

Volumn 173, Issue 2, 2004, Pages 261-267

  De Grooth, Greetje J ^a   Smilde, Tineke J ^b   Van Wissen, Sanne ^a   Klerkx, Anke H E M ^a   Zwinderman, Aeilko H ^a   Fruchart, Jean Charles ^c   Kastelein, John J P ^a   Stalenhoef, Anton F H ^b   Kuivenhoven, Jan Albert ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIV LILLE   (France)

Author keywords

Cholesteryl ester transfer protein; High density lipoprotein cholesterol; Low density lipoprotein cholesterol; Statin

Indexed keywords

ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ARTERIOSCLEROSIS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HEPTANOIC ACIDS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LINEAR MODELS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROBABILITY; PROGNOSIS; PYRROLES; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SIMVASTATIN; TREATMENT OUTCOME; TUNICA MEDIA;

EID: 1842767407     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2003.11.020     Document Type: Article

References (31)

1. Tall A.R. Plasma cholesteryl ester transfer protein. J. Lipid Res. 34:1993;1255-1274.
2. Barter P.J. Hugh Sinclair Lecture: the regulation and remodelling of HDL by plasma factors. Atheroscler. Suppl. 3:2002;39-47.
3. Guerin M., Le Goff W., Lassel T.S.et al. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler. Thromb. Vasc. Biol. 21:2001;282-288.
4. Inazu A., Brown M.L., Hesler C.B.et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 323:1990;1234-1238.
5. Brown M.L., Inazu A., Hesler C.B.et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature. 342:1989;448-451.
6. Gotto A.M. Jr. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. Circulation. 103:2001;2213-2218.
7. Okamoto H., Yonemori F., Wakitani K.et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 406:2000;203-207.
8. Sugano M., Makino N., Sawada S.et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 273:1998;5033-5036.
9. de Grooth G.J., Kuivenhoven J.A., Stalenhoef A.F.H.et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 105:2002;2159-2165.
10. Glomset J.A. The plasma lecithins: cholesterol acyltransferase reaction. J. Lipid Res. 9:1968;155-167.
11. Marotti K.R., Castle C.K., Boyle T.P.et al. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 364:1993;73-75.
12. Foger B., Chase M., Amar M.J.et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J. Biol. Chem. 274:1999;36912-36920.
13. Hirano K., Yamashita S., Nakajima N.et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler. Thromb. Vasc. Biol. 17:1997;1053-1059.
14. Koizumi J., Mabuchi H., Yoshimura A.et al. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis. 58:1985;175-186.
15. Zhong S., Sharp D.S., Grove J.S.et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97:1996;2917-2923.
16. Smilde T.J., van Wissen S., Wollersheim H.et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 357:2001;577-581.
17. Luc G., Bard J.M., Ferrieres J.et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler. Thromb. Vasc. Biol. 22:2002;1155-1161.
18. Lopes-Virella M.F., Virella G., Evans G.et al. Immunonephelometric assay of human apolipoprotein AI. Clin. Chem. 26:1980;1205-1208.
19. Ulloa N., Arteaga E., Bustos P.et al. Sequential estrogen-progestin replacement therapy in healthy postmenopausal women: effects on cholesterol efflux capacity and key proteins regulating high-density lipoprotein levels. Metabolism. 51:2002;1410-1417.
20. Otvos J.D. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin. Lab. 48:2002;171-180.
21. Smilde T.J., Wollersheim H., Van Langen H.et al. Reproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increased intima-media thickness. Clin. Sci. (Lond.). 93:1997;317-324.
22. McPherson R., Mann C.J., Tall A.R.et al. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. Arterioscler. Thromb. 11:1991;797-804.
23. Inazu A., Koizumi J., Kajinami K.et al. Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. Atherosclerosis. 145:1999;405-413.
24. Kunitake S.T., Mendel C.M., Hennessy L.K. Interconversion between apolipoprotein A-I-containing lipoproteins of pre-beta and alpha electrophoretic mobilities. J. Lipid Res. 33:1992;1807-1816.
25. Rye K.A., Hime N.J., Barter P.J. Evidence that cholesteryl ester transfer protein-mediated reductions in reconstituted high density lipoprotein size involve particle fusion. J. Biol. Chem. 272:1997;3953-3960.
26. Rye K.A., Clay M.A., Barter P.J. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis. 145:1999;227-238.
27. Freedman D.S., Otvos J.D., Jeyarajah E.J.et al. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 18:1998;1046-1053.
28. Kunz F., Pechlaner C., Erhart R.et al. HDL and plasma phospholipids in coronary artery disease. Arterioscler. Thromb. 14:1994;1146-1150.
29. Haraki T., Inazu A., Yagi K.et al. Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency. Atherosclerosis. 132:1997;229-236.
30. Toyota Y., Yamamura T., Miyake Y.et al. Low density lipoprotein (LDL) binding affinity for the LDL receptor in hyperlipoproteinemia. Atherosclerosis. 147:1999;77-86.
31. Phillips N.R., Waters D., Havel R.J. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 88:1993;2762-2770.